Connection

Co-Authors

This is a "connection" page, showing publications co-authored by BARRY W FEIG and JOHN M SKIBBER.
Connection Strength

1.466
  1. Multimodality salvage of recurrent disease after local excision for rectal cancer. Dis Colon Rectum. 2012 Dec; 55(12):1213-9.
    View in: PubMed
    Score: 0.109
  2. Local excision after preoperative chemoradiation results in an equivalent outcome to total mesorectal excision in selected patients with T3 rectal cancer. Ann Surg Oncol. 2010 Feb; 17(2):441-7.
    View in: PubMed
    Score: 0.088
  3. Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal. Ann Surg Oncol. 2007 Feb; 14(2):478-83.
    View in: PubMed
    Score: 0.072
  4. Outcome after curative resection for locally recurrent rectal cancer. Dis Colon Rectum. 2006 Feb; 49(2):175-82.
    View in: PubMed
    Score: 0.068
  5. Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients. Int J Radiat Oncol Biol Phys. 2004 Nov 15; 60(4):1098-105.
    View in: PubMed
    Score: 0.062
  6. Predicting the node-negative mesorectum after preoperative chemoradiation for locally advanced rectal carcinoma. J Gastrointest Surg. 2004 Jan; 8(1):56-62; discussion 62-3.
    View in: PubMed
    Score: 0.059
  7. Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol. 2001 Apr; 24(2):107-12.
    View in: PubMed
    Score: 0.049
  8. Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2000 Jun 01; 47(3):713-8.
    View in: PubMed
    Score: 0.046
  9. Clinical, pathologic, and economic parameters of laparoscopic colon resection for cancer. Am J Surg. 1998 Dec; 176(6):554-8.
    View in: PubMed
    Score: 0.041
  10. Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal. Am J Clin Oncol. 2017 Dec; 40(6):555-560.
    View in: PubMed
    Score: 0.039
  11. Comparative effectiveness of primary tumor resection in patients with stage IV colon cancer. Cancer. 2017 04 01; 123(7):1124-1133.
    View in: PubMed
    Score: 0.035
  12. DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics. J Clin Oncol. 2016 09 01; 34(25):3039-46.
    View in: PubMed
    Score: 0.035
  13. Impact of multimodal therapy in locally recurrent rectal cancer. Br J Surg. 2016 May; 103(6):753-762.
    View in: PubMed
    Score: 0.034
  14. Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains. JAMA Surg. 2015 May; 150(5):402-9.
    View in: PubMed
    Score: 0.032
  15. Time trend analysis of primary tumor resection for stage IV colorectal cancer: less surgery, improved survival. JAMA Surg. 2015 Mar 01; 150(3):245-51.
    View in: PubMed
    Score: 0.032
  16. Risk-adjusted pathologic margin positivity rate as a quality indicator in rectal cancer surgery. J Clin Oncol. 2014 Sep 20; 32(27):2967-74.
    View in: PubMed
    Score: 0.031
  17. Functional deficits and symptoms of long-term survivors of colorectal cancer treated by multimodality therapy differ by age at diagnosis. J Gastrointest Surg. 2015 Jan; 19(1):180-8; discussio 188.
    View in: PubMed
    Score: 0.031
  18. Intraoperative radiation therapy for locally advanced primary and recurrent colorectal cancer: ten-year institutional experience. J Surg Oncol. 2014 Jun; 109(7):652-8.
    View in: PubMed
    Score: 0.030
  19. Impact of ileostomy-related complications on the multidisciplinary treatment of rectal cancer. Ann Surg Oncol. 2014 Feb; 21(2):507-12.
    View in: PubMed
    Score: 0.029
  20. A novel risk-adjusted nomogram for rectal cancer surgery outcomes. JAMA Surg. 2013 Aug; 148(8):769-77.
    View in: PubMed
    Score: 0.029
  21. Comparative analysis of lymph node metastases in patients with ypT0-2 rectal cancers after neoadjuvant chemoradiotherapy. Dis Colon Rectum. 2013 Feb; 56(2):135-41.
    View in: PubMed
    Score: 0.028
  22. Morbidity of staged proctectomy after hepatectomy for colorectal cancer: a matched case-control analysis. Ann Surg Oncol. 2013 Feb; 20(2):482-90.
    View in: PubMed
    Score: 0.027
  23. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol. 2012 May 20; 30(15):1770-6.
    View in: PubMed
    Score: 0.026
  24. Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base. Ann Surg Oncol. 2012 Sep; 19(9):2814-21.
    View in: PubMed
    Score: 0.026
  25. Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma. Cancer. 2011 Aug 15; 117(16):3713-22.
    View in: PubMed
    Score: 0.024
  26. Long-term survival and recurrence outcomes following surgery for distal rectal cancer. Ann Surg Oncol. 2010 Nov; 17(11):2863-9.
    View in: PubMed
    Score: 0.023
  27. Clinical significance of acellular mucin in rectal adenocarcinoma patients with a pathologic complete response to preoperative chemoradiation. Ann Surg. 2010 Feb; 251(2):261-4.
    View in: PubMed
    Score: 0.022
  28. Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation. Int J Radiat Oncol Biol Phys. 2010 May 01; 77(1):60-5.
    View in: PubMed
    Score: 0.022
  29. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):824-30.
    View in: PubMed
    Score: 0.021
  30. Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical course. Int J Radiat Oncol Biol Phys. 2009 Jul 01; 74(3):818-23.
    View in: PubMed
    Score: 0.021
  31. Age-, race-, and ethnicity-related differences in the treatment of nonmetastatic rectal cancer: a patterns of care study from the national cancer data base. Ann Surg Oncol. 2008 Nov; 15(11):3036-47.
    View in: PubMed
    Score: 0.020
  32. Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2008 Jul 15; 71(4):1175-80.
    View in: PubMed
    Score: 0.019
  33. Sentinel lymph node evaluation does not improve staging accuracy in colon cancer. Ann Surg Oncol. 2008 Jan; 15(1):46-51.
    View in: PubMed
    Score: 0.019
  34. Are we undertreating rectal cancer in the elderly? An epidemiologic study. Ann Surg. 2007 Aug; 246(2):215-21.
    View in: PubMed
    Score: 0.019
  35. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer. 2007 May 01; 109(9):1750-5.
    View in: PubMed
    Score: 0.019
  36. Pelvic exenteration affords safe and durable treatment for locally advanced rectal carcinoma. Ann Surg Oncol. 2007 Jun; 14(6):1870-7.
    View in: PubMed
    Score: 0.018
  37. Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2006 Nov 01; 66(3):762-71.
    View in: PubMed
    Score: 0.018
  38. Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys. 2006 Dec 01; 66(5):1378-83.
    View in: PubMed
    Score: 0.018
  39. Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer. Am J Clin Oncol. 2006 Jun; 29(3):219-24.
    View in: PubMed
    Score: 0.017
  40. Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival? Am J Clin Oncol. 2006 Jun; 29(3):232-9.
    View in: PubMed
    Score: 0.017
  41. The addition of continuous infusion 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2003 Sep 01; 57(1):84-9.
    View in: PubMed
    Score: 0.014
  42. Chemoradiation for adenocarcinoma of the anus. Int J Radiat Oncol Biol Phys. 2003 Mar 01; 55(3):669-78.
    View in: PubMed
    Score: 0.014
  43. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index. Cancer. 2003 Mar 01; 97(5):1195-202.
    View in: PubMed
    Score: 0.014
  44. Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma. Cancer. 2003 Jan 15; 97(2):517-24.
    View in: PubMed
    Score: 0.014
  45. Elective groin irradiation is not indicated for patients with adenocarcinoma of the rectum extending to the anal canal. Int J Radiat Oncol Biol Phys. 2001 Nov 01; 51(3):741-7.
    View in: PubMed
    Score: 0.013
  46. T4 rectal cancer treated with preoperative chemoradiation to the posterior pelvis followed by multivisceral resection: patterns of failure and limitations of treatment. Int J Radiat Oncol Biol Phys. 2001 Sep 01; 51(1):176-83.
    View in: PubMed
    Score: 0.013
  47. Carcinoid tumors of the rectum: effect of size, histopathology, and surgical treatment on metastasis free survival. Cancer. 1997 Apr 01; 79(7):1294-8.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.